Treatment for AMD: the Autorité fines 3 laboratories for abusive practices* The Autorité de la concurrence has imposed fines worth a total of €444 million on three pharmaceutical companies, Novartis, Roche and Genentech, for abusive practices designed to sustain the sales of Lucentis for AMD treatment to the detriment of Avastin (a competitive medicinal product that is 30 times cheaper). Background Age-related macular degeneration (AMD) is the main cause of low vision for people over 50 in industrialized countries. It causes severe impairment of central vision, which is particularly present in the form of dark spots perceived by the patient in the middle of its vision. The Genentech laboratory has developed a drug, Lucentis, to treat AMD. It also developed another medicine, an
Share on
|
|
The French Competition Authority fines three laboratories for abusive practices (Novartis / Roche / Genentech)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
